Home > Research > Publications & Outputs > Hospitalisation and mortality risk of SARS-COV-...

Research

Associated organisational units

Links

Text available via DOI:

Keywords

View graph of relations

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. / Webster, H H; Nyberg, T; Sinnathamby, M A et al.
In: Nature Communications, Vol. 13, No. 1, 6053, 13.10.2022.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Webster, HH, Nyberg, T, Sinnathamby, MA, Aziz, NA, Ferguson, N, Seghezzo, G, Blomquist, PB, Bridgen, J, Chand, M, Groves, N, Myers, R, Hope, R, Ashano, E, Lopez-Bernal, J, De Angelis, D, Dabrera, G, Presanis, AM & Thelwall, S 2022, 'Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England', Nature Communications, vol. 13, no. 1, 6053. https://doi.org/10.1038/s41467-022-33740-9

APA

Webster, H. H., Nyberg, T., Sinnathamby, M. A., Aziz, N. A., Ferguson, N., Seghezzo, G., Blomquist, P. B., Bridgen, J., Chand, M., Groves, N., Myers, R., Hope, R., Ashano, E., Lopez-Bernal, J., De Angelis, D., Dabrera, G., Presanis, A. M., & Thelwall, S. (2022). Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nature Communications, 13(1), Article 6053. https://doi.org/10.1038/s41467-022-33740-9

Vancouver

Webster HH, Nyberg T, Sinnathamby MA, Aziz NA, Ferguson N, Seghezzo G et al. Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nature Communications. 2022 Oct 13;13(1):6053. doi: 10.1038/s41467-022-33740-9

Author

Webster, H H ; Nyberg, T ; Sinnathamby, M A et al. / Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. In: Nature Communications. 2022 ; Vol. 13, No. 1.

Bibtex

@article{a869f9d07b8e4313830319b87f16bce4,
title = "Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England",
abstract = "The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.",
keywords = "COVID-19/epidemiology, Cohort Studies, Hospitalization, Humans, SARS-CoV-2/genetics",
author = "Webster, {H H} and T Nyberg and Sinnathamby, {M A} and Aziz, {N Abdul} and N Ferguson and G Seghezzo and Blomquist, {P B} and J Bridgen and M Chand and N Groves and R Myers and R Hope and E Ashano and J Lopez-Bernal and {De Angelis}, D and G Dabrera and Presanis, {A M} and S Thelwall",
note = "{\textcopyright} 2022. Crown.",
year = "2022",
month = oct,
day = "13",
doi = "10.1038/s41467-022-33740-9",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

AU - Webster, H H

AU - Nyberg, T

AU - Sinnathamby, M A

AU - Aziz, N Abdul

AU - Ferguson, N

AU - Seghezzo, G

AU - Blomquist, P B

AU - Bridgen, J

AU - Chand, M

AU - Groves, N

AU - Myers, R

AU - Hope, R

AU - Ashano, E

AU - Lopez-Bernal, J

AU - De Angelis, D

AU - Dabrera, G

AU - Presanis, A M

AU - Thelwall, S

N1 - © 2022. Crown.

PY - 2022/10/13

Y1 - 2022/10/13

N2 - The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.

AB - The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.

KW - COVID-19/epidemiology

KW - Cohort Studies

KW - Hospitalization

KW - Humans

KW - SARS-CoV-2/genetics

U2 - 10.1038/s41467-022-33740-9

DO - 10.1038/s41467-022-33740-9

M3 - Journal article

C2 - 36229438

VL - 13

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 6053

ER -